Jerusalem, Israel, September 22, 05 --- Gamida Cell Ltd., announced today that Gamida Cell CEO Dr. Yael Margolin will present on the topic of Expanded Stem Cell Therapeutics: Status and Progress, at the UBS Global Life Sciences Conference, Monday, September 26, 2005 at 4:00 PM, at the Grand Hyatt in New York, NY.
“Gamida Cell is at the forefront of the development of expanded stem cell therapeutics. It has been a busy and an exciting year, one which we believe will prove to be the precursor to even more great things to come. I look forward to briefing attendees on the status of our lead product, StemEx®,” said Gamida Cell CEO Dr. Yael Margolin.
Gamida Cell’s Phase I/II study of StemEx® for the treatment of leukemia and lymphoma, which completed in January 2005, showed good safety. A pivotal study is scheduled to begin in the U.S., Europe and Israel in Q1 2006. In Q1 2005, Gamida Cell and Teva Pharmaceuticals established a joint venture to develop and market StemEx®. The joint venture is funded with $25M from Teva and is equally owned and jointly managed by Gamida Cell and Teva. The market launch for StemEx® is anticipated for 2008. StemEx® was granted an orphan drug designation by the FDA in March 2005.
Gamida Cell Ltd., (www.gamida-cell.com), is a leader in the expansion of hematopoietic (blood) stem cell therapeutics in clinical development for cancer, as well as future regenerative cell-based medicines including cardiac and pancreatic diseases. The combined market potential of Gamida Cell’s expanded stem cell products is estimated at $30 billion worldwide. Gamida Cell is currently pursuing partnerships and strategic alliances. Investors include Elscint (Europe-Israel), Biomedical Investments, Denali Ventures, Teva Pharmaceutical Industries, Auriga Ventures, Pamot and Comsor.
For additional information: Marjie Hadad, Media Liaison, firstname.lastname@example.org, +972-54-536-5220.